To develop transformative biological therapies that restore chronic wounds, starting with diabetic foot ulcers.
The need is urgent, and current treatments often fall short.
At Omnio, we harness the unique power of plasminogen to unlock new therapies for chronic wounds and inflammation.
Starting with diabetic foot ulcers, our biologically driven platform is paving the way toward better healing,
reduced scarring, and a future free from persistent infections.
Our therapy is built on decades of research at Umeå University, where Professor Tor Ny uncovered the essential role
of plasminogen in wound healing. Now, our team expands from Sweden, to Spain, the UK, Denmark and India.
We are getting ready to perform our phase IIa/b trials in 2026 and 2027.
We are scientists, clinicians, and entrepreneurs with deep expertise in regenerative biology, chronic inflammation,
and drug development—with a proven track record in global wound care innovation
Our team combines translational research, biotech strategy, clinical strategy and manufacturing readiness.
With the support of a strong board and academic partners, we’re building a company built to scale—and built to last.
Felipe Velasquez
CEO
Felipe Velasquez is a seasoned Life Sciences executive with over 25 years of experience driving strategic growth and operational excellence in the pharmaceutical, biotech and healthcare sectors.
Read moreHis track record includes launching and scaling ventures across pharmaceuticals, diagnostics, and healthcare specialty networks. He has successfully led M&A initiatives, out licensing deals, forging strategic partnerships, and optimizing business operations for sustainable expansion.
With a strong foundation in finance, marketing, and operations, Felipe brings a global perspective, having worked across eight European countries, the U.S., Latin America, and India. His ability to drive innovation and execute strategic initiatives makes him a valuable leader in the biotech and healthcare industries.
Read lessTor Ny
Head of RnD
Tor Ny is a senior professor in Medical Biochemistry with over 30 years of research experience exploring the therapeutic potential of plasminogen in wound healing.
Read moreA pioneer in the field, [Name] was among the first to demonstrate the regenerative effects of plasminogen as a wound healing drug candidate. Their extensive academic and clinical work has helped unlock the role of plasminogen across multiple therapeutic indications.
With a deep commitment to advancing science, [Name] has contributed significantly to the understanding of inflammation resolution, tissue repair, and the biological pathways that underlie natural healing processes. Their research forms a key part of Omnio’s scientific foundation.
Read lessHenrik Bergdahl
Chief financial officer
Anders Vagnø Pedersen
CMC manager
Anders is a Senior CMC Advisor with over 35 years of experience in the Biotech and Pharma industry, specializing in process development and regulatory strategy.
Read moreThroughout their career, [Name] has built deep expertise across upstream and downstream process development, formulation, patent strategy, and project management.
They have successfully led multiple GMP CMC product filings across Europe, the U.S., and Japan—bringing a strong track record in navigating regulatory pathways and ensuring quality and compliance throughout the development cycle.
Read lessJoanne James
Clinical development manager
Joanne is a multi-award-winning innovator with over 25 years of experience driving clinical strategy and development in medical devices and pharmaceuticals.
Read moreShe has played a pivotal role in product development, pre-clinical and clinical program design, and execution—leading to multiple strategic acquisitions and regulatory approvals in the wound care field.
Recent achievements include leading evidence generation that contributed to Convatec’s acquisition of Thirty Technology’s wound franchise in 2023, and advancing pre-clinical studies supporting FDA approval of Filsuvez for Epidermolysis Bullosa (Amryt Pharma, 2022).
Read lessFelipe Velasquez
CEO
Felipe Velasquez is a seasoned Life Sciences executive with over 25 years of experience driving strategic growth and operational excellence in the pharmaceutical, biotech and healthcare sectors.
Read moreHis track record includes launching and scaling ventures across pharmaceuticals, diagnostics, and healthcare specialty networks. He has successfully led M&A initiatives, out licensing deals, forging strategic partnerships, and optimizing business operations for sustainable expansion.
With a strong foundation in finance, marketing, and operations, Felipe brings a global perspective, having worked across eight European countries, the U.S., Latin America, and India. His ability to drive innovation and execute strategic initiatives makes him a valuable leader in the biotech and healthcare industries.
Read lessFelipe Velasquez
CEO
Felipe Velasquez is a seasoned Life Sciences executive with over 25 years of experience driving strategic growth and operational excellence in the pharmaceutical, biotech and healthcare sectors.
Read moreHis track record includes launching and scaling ventures across pharmaceuticals, diagnostics, and healthcare specialty networks. He has successfully led M&A initiatives, out licensing deals, forging strategic partnerships, and optimizing business operations for sustainable expansion.
With a strong foundation in finance, marketing, and operations, Felipe brings a global perspective, having worked across eight European countries, the U.S., Latin America, and India. His ability to drive innovation and execute strategic initiatives makes him a valuable leader in the biotech and healthcare industries.
Read lessFelipe Velasquez
CEO
Felipe Velasquez is a seasoned Life Sciences executive with over 25 years of experience driving strategic growth and operational excellence in the pharmaceutical, biotech and healthcare sectors.
Read moreHis track record includes launching and scaling ventures across pharmaceuticals, diagnostics, and healthcare specialty networks. He has successfully led M&A initiatives, out licensing deals, forging strategic partnerships, and optimizing business operations for sustainable expansion.
With a strong foundation in finance, marketing, and operations, Felipe brings a global perspective, having worked across eight European countries, the U.S., Latin America, and India. His ability to drive innovation and execute strategic initiatives makes him a valuable leader in the biotech and healthcare industries.
Read less
info@omnio.se
Uminova Science Park
Tvistevägen 48 SE- 907 19 Umeå Sweden
LinkedIn